Industries > Pharma > Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027

Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027

Leading IVD Companies in the US, Europe and Asia

PUBLISHED: 18 November 2016
PAGES: 185
PRODUCT CODE: PHA0152
SUBMARKET: Medical Devices

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0152 Categories: , Tags: ,

What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain’s new report Medical Devices Leader Series – Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia shows you the prospects of leading IVD companies to 2027.

Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027.

Our report forecasts to 2027 the overarching IVD market and its main segments:
• Point-of-care (POC) tests
• Clinical chemistry
• Immunochemistry
• Haematological diagnostics
• Microbiological applications
• Genetic testing agents
• Other products

Medical Devices Leader Series

This report provides profiles, discussions and financial analyses – including revenue forecasts to 2027 – for top US IVD companies:
• Danaher
• Abbott Laboratories
• Johnson & Johnson (J&J)
• Bio-Rad
• Becton Dickinson
• Thermo Fisher Scientific

Our report shows you developments and revenue forecasts to 2027 for leading diagnostics companies based in Europe:
• Roche
• Siemens
• bioMérieux

This report also provides outlooks and revenue forecasts to 2027 for top Japanese companies developing and producing IVD tests:
• Sysmex
• Arkray

Our work assesses other companies progressing in that field. There you discover activities of these emerging players and their associated organisations:
• Dako (Agilent Technologies)
• Genomic Health
• Laboratory Corporation of America (LabCorp)
• MDxHealth
• Myriad Genetics
• QIAGEN

Our 185 page report provides 65 tables and 75 figures covering 7 different IVD submarkets, leading companies in the US, Europe and Asia.

Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027


Latest Pharma news

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

READ

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

READ

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

READ

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

READ

Categories

Category